Abstract
Context: Previous studies of Ginkgo biloba extract (GbE) in patients with various forms of cognitive impairment or dementia have shown promising results. Objective: To determine the clinical efficacy of GbE in mild to moderate dementia of the Alzheimer type. Design: Randomized, placebo-controlled, double-blind, parallel-group, multicenter trial. Setting: Outpatient clinics of universities and private research centers specialized in dementia. Patients: 513 outpatients with uncomplicated dementia of the Alzheimers type scoring 10 to 24 on the Mini-Mental State Examination and less than 4 on the modified Hachinski Ischemic Score, free of other serious illnesses and not requiring continuous treatment with any psychoactive drug. Intervention: 26-week treatment with GbE at daily doses of 120 mg or 240 mg or placebo. Main Outcomes: Cognitive subscale of the Alzheimers Disease Assessment Scale (ADAS-cog), Alzheimers Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC). Results: There were no significant between-group differences for the whole sample. There was little cognitive and functional decline of the placebo-treated patients, however. For a subgroup of patients with neuropsychiatric symptoms there was a greater decline of placebo-treated patients and significantly better cognitive performance and global assessment scores for the patients on GbE. Conclusion: The trial did not show efficacy of GbE, however, the lack of decline of the placebo patients may have compromised the sensitivity of the trial to detect a treatment effect. Thus, the study remains inconclusive with respect to the efficacy of GbE.
Keywords: Ginkgo biloba, dementia, Alzheimer's disease, treatment, randomized controlled trial
Current Alzheimer Research
Title: A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimers Type
Volume: 2 Issue: 5
Author(s): Lon S. Schneider, Steven T. DeKosky, Martin R. Farlow, Pierre N. Tariot, Robert Hoerr and Meinhard Kieser
Affiliation:
Keywords: Ginkgo biloba, dementia, Alzheimer's disease, treatment, randomized controlled trial
Abstract: Context: Previous studies of Ginkgo biloba extract (GbE) in patients with various forms of cognitive impairment or dementia have shown promising results. Objective: To determine the clinical efficacy of GbE in mild to moderate dementia of the Alzheimer type. Design: Randomized, placebo-controlled, double-blind, parallel-group, multicenter trial. Setting: Outpatient clinics of universities and private research centers specialized in dementia. Patients: 513 outpatients with uncomplicated dementia of the Alzheimers type scoring 10 to 24 on the Mini-Mental State Examination and less than 4 on the modified Hachinski Ischemic Score, free of other serious illnesses and not requiring continuous treatment with any psychoactive drug. Intervention: 26-week treatment with GbE at daily doses of 120 mg or 240 mg or placebo. Main Outcomes: Cognitive subscale of the Alzheimers Disease Assessment Scale (ADAS-cog), Alzheimers Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC). Results: There were no significant between-group differences for the whole sample. There was little cognitive and functional decline of the placebo-treated patients, however. For a subgroup of patients with neuropsychiatric symptoms there was a greater decline of placebo-treated patients and significantly better cognitive performance and global assessment scores for the patients on GbE. Conclusion: The trial did not show efficacy of GbE, however, the lack of decline of the placebo patients may have compromised the sensitivity of the trial to detect a treatment effect. Thus, the study remains inconclusive with respect to the efficacy of GbE.
Export Options
About this article
Cite this article as:
Schneider S. Lon, DeKosky T. Steven, Farlow R. Martin, Tariot N. Pierre, Hoerr Robert and Kieser Meinhard, A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimers Type, Current Alzheimer Research 2005; 2 (5) . https://dx.doi.org/10.2174/156720505774932287
| DOI https://dx.doi.org/10.2174/156720505774932287 |
Print ISSN 1567-2050 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
Alzheimer's Disease Blood Tests: Advancements and the Future of Point-of-Care
The recent FDA approval of lecanemab (Leqembi), the first treatment for Alzheimer’s disease targeting early stages and mild cognitive impairment, has brought renewed hope for the therapeutic future of this devastating condition. While the exact causes and mechanisms of Alzheimer’s disease remain obscure, there is an urgent consensus on the ...read more
Atypical Alzheimer’s disease: towards inclusion into disease-modifying clinical trials
Patients with non-amnestic atypical variants of Alzheimer’s disease show considerable heterogeneity in clinical characteristics, including visual, language and behavioral impairments, and often have a young age onset. Current clinical trials for anti-amyloid therapies do not sufficiently account for this heterogeneity, and it is unclear whether current treatments tested in amnestic ...read more
Drug Discovery and Possible Therapeutic Developments in Neurological Disorders Alzheimer’s Disease and Tauopathy
A critical appraisal Alzheimer's disease (AD) is a devastating mental illness in society and the etiology and pathogenesis of AD are still poorly understood. One of the key hallmark pathological proteins of AD is tau, where the pathophysiology and the functional relationships between hyperphosphorylation of tau and synaptic damage in ...read more
Early nutritional intervention and physical activity in the prevention of Alzheimer's disease and other dementias
The aim is to broaden the knowledge about the impact of the consumption of food ingredients, diet ingredients, methods of processing of food raw materials as well as the impact of composing of diets on the possibility of preventing Alzheimer's disease and other types of dementia at each stage of ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Clinical Spectrum, Diagnosis, Pathogenesis and Treatment of Hashimotos Encephalopathy (Recurrent Acute Disseminated Encephalomyelitis)
Current Medicinal Chemistry Familial Early-Onset Alzheimer's Caused by Novel Genetic Variant and APP Duplication: A Cross-Sectional Study
Current Alzheimer Research Anti-Viral Agents in Neurodegenerative Disorders: New Paradigm for Targeting Alzheimer’s Disease
Recent Patents on Anti-Infective Drug Discovery How Should We Deal with Missing Data in Clinical Trials Involving Alzheimers Disease Patients?
Current Alzheimer Research Voice Markers of Lexical Access in Mild Cognitive Impairment and Alzheimer's Disease
Current Alzheimer Research Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research Electrochemical Biosensor for the Detection of Glycated Albumin
Current Alzheimer Research Identification of Electrophysiological Changes in Alzheimer's Disease: A Microarray Based Transcriptomics and Molecular Pathway Analysis Study
CNS & Neurological Disorders - Drug Targets Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study
CNS & Neurological Disorders - Drug Targets Clinical, Genetic, and Neuroimaging Features of Early Onset Alzheimer Disease: The Challenges of Diagnosis and Treatment
Current Alzheimer Research Tumor Necrosis Factor Blocking Therapy and Congestive Heart Failure in Patients with Inflammatory Rheumatic Disorders: A Systematic Review
Current Medicinal Chemistry A Brief Comparative Look at Experimental Memory Editing Techniques for Cognitive Dysfunction
Current Alzheimer Research Mediterranean Diet and Low-grade Subclinical Inflammation: The Moli-sani Study
Endocrine, Metabolic & Immune Disorders - Drug Targets Cerebral White Matter Lesions, Risk of Stroke and Cerebrovascular Protection with Angiotensin Receptor Blockers
Current Drug Therapy The Efficacy of Vitamin K, A Member Of Naphthoquinones in the Treatment of Cancer: A Systematic Review and Meta-Analysis
Current Cancer Drug Targets Vascular Contribution to Alzheimer Disease: Predictors of Rapid Progression
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Current Alzheimer Research Adult Neurogenesis, Neural Stem Cells and Alzheimers Disease: Developments, Limitations, Problems and Promises
Current Alzheimer Research Platelet GPIIb/IIIa Receptor Antagonists in Human Ischemic Brain Disease
Current Vascular Pharmacology Relevance of Aβ 1-42 Intrahippocampal Injection as An Animal Model of Inflamed Alzheimers Disease Brain
Current Alzheimer Research





